Atrial fibrillation Medical Services in China

Atrial fibrillation (AFib) is the most common sustained cardiac arrhythmia, characterized by disorganized electrical activity in the atria, resulting in rapid and irregular ventricular response. It significantly increases the risk of stroke, heart failure, and systemic embolism due to ineffective atrial contraction and stasis-induced thrombus formation—particularly in the left atrial appendage. AFib is classified as paroxysmal, persistent, or long-standing persistent based on duration and reversibility. Diagnosis relies on electro), Holter monitoring, and echocardiography; management encompasses rate control (e.g., beta-blockers, calcium channel blockers), rhythm, cardioversion), anticoagulation (DOACs or warfarin), and catheter ablation—especially for symptomatic, drug-refractory cases. Pulmonary vein isolation (PVI) remains the cornerstone ablation strategy, increasinglyanatomic mapping systems and contact-force sensing catheters.

China offers distinct advantages for AFib treatment: leading cardiovascular centers—such as Fuwai Hospital (National Center for Cardiovascular Diseases) and Shanghai Ruijin Hospital—rank among Asia’s top-tier institutions, with electrophysiologists performing over 10,000 ablations annually. State-of-the-art infrastructure includes MRI-guided ablation platforms, robotic navigation systems, and real-time intracardiac echocardiography. Clinical outcomes match or exceed international benchmarks: single-procedure freedom from AFib at 12 months exceeds 75% for paroxysmal cases, supported by robust registry data. Crucially, comprehensive care—including pre-procedure assessment, cryoballoon or radiofrequency ablation, and post-ablation monitoring—is delivered at approximately 40–60% of costs in the US or Western Europe, without compromising quality or safety standards.

As a dedicated medical tourism agency, we facilitate seamless access to these high-value services for international patients: vetting JCI-accredited hospitals, coordinating appointments with board-certified electrophysiologists, providing transparent, all-inclusive pricing (covering diagnostics, procedure, hospital stay, and follow-up), and offering end-to-end support—from visa assistance and travel logistics to bilingual clinical coordination and recovery accommodation.

Treatment Options & Itemized Cost Breakdown: Atrial Fibrillation (Cardiology Department)

Non-Surgical / Conservative Management

*Target Criteria:* Asymptomatic or mild symptoms, low stroke risk (CHA₂DS₂-VASc ≤1), stable hemodynamics, no structural heart disease contraindicating rate control.

• •Rate Control Medications (e.g., bisoprolol, digoxin, diltiazem):

- ECG monitoring (per visit): $8 - Liver/kidney function + electrolytes (baseline + q3mo): $45 - Annual echocardiogram (TTE): $110

• •Rhythm Control Medications (e.g., amiodarone, dronedarone, propafenone):

- Baseline & q3mo thyroid function + LFTs + chest X-ray: $75 - Annual Holter monitor (24-hr): $95

• •Anticoagulation Therapy (DOACs preferred: apixaban, rivaroxaban, edoxaban):

- Annual renal function + CBC: $30 - No routine INR monitoring required (vs. warfarin: $15/visit × 12 = $180/year)

Surgical / Procedural / Interventional Options

*Eligibility Criteria:* Symptomatic AF refractory to ≥2 antiarrhythmics; paroxysmal/persistent AF; LA diameter <55 mm; no contraindications to ablation (e.g., active endocarditis, severe LA thrombus).

• •Catheter Ablation (PVI ± substrate modification):

- Pre-op workup (TTE, CT angiography, blood coagulation panel, HbA1c, hepatitis screen): $320 - Hospital stay (3–5 days): $1,100–$1,800 - Post-ablation 7-day event monitor: $130

• •Surgical Maze (concomitant during CABG/valve surgery):

- *Not performed standalone in China due to invasiveness and lack of superiority over catheter ablation.*

Special / Complex Condition Options

• •Long-Standing Persistent AF (>12 months) with LA enlargement (>55 mm) or prior failed ablation:

- Pre-op cardiac MRI + advanced fibrosis mapping: $480

• •AF with High Stroke Risk + Contraindication to Anticoagulants (e.g., recurrent GI bleeding):

- Pre-op TEE + CT + anesthesia assessment: $390

Quick Selection Guide

• •<65 years, paroxysmal AF, no comorbidities, budget >$5k: First-line catheter ablation — highest long-term freedom from AF and drug burden.
• •≥75 years, CHA₂DS₂-VASc ≥3, frailty or bleeding history: DOAC + rate control — avoids procedural risk; optimal safety/cost balance.
• •Persistent AF + diabetes/hypertension + LA size 48–54 mm: Rhythm control drugs + early ablation referral — delays progression; ablation success remains >70%.
• •Recurrent AF post-ablation + LA fibrosis on MRI: Hybrid ablation — only option with proven efficacy in this subgroup.
• •Contraindicated anticoagulation + high stroke risk: LAAC — definitive stroke prevention without lifelong anticoagulation.